Bladder cancer remains a persistent challenge in oncology, demanding meaningful innovation. Through a multi-faceted approach to immunotherapy, ImmunityBio is focused on redefining how this disease is treated - grounded in science, guided by patients, and driven by our mission. This Bladder Cancer Awareness Month, we recognize the resilience of patients, the support of caregivers, and the guidance of healthcare providers who continue to push progress forward. Learn more about our work: https://lnkd.in/gJmy4pZg
ImmunityBio, Inc.
Biotechnology Research
San Diego, CA 33,584 followers
Outsmart Your Disease™
About us
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
- Website
-
https://www.ImmunityBio.com
External link for ImmunityBio, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Founded
- 2014
- Specialties
- Immunotherapy, Cancer, Infectious Diseases, Natural Killer, T Cell, Vaccines, Oncology, Vaccine, Fusion Proteins, Clinical Trials, COVID-19, and Cell Therapy
Locations
Employees at ImmunityBio, Inc.
Updates
-
This weekend, we joined the Bladder Cancer Advocacy Network (BCAN) Walk in Los Angeles, coming together with a community united by strength, resilience, and shared purpose. Every step reflects the ongoing journey faced by those impacted by bladder cancer and the collective commitment to raising awareness and supporting one another along the way. Get involved in a walk near you: https://lnkd.in/g2wzqxHR
-
-
-
-
-
+1
-
-
Access to innovative cancer therapies continues to expand. ANKTIVA® is now available in Saudi Arabia for patients with bladder and lung cancers, marking an important step in ImmunityBio’s global efforts to reach more patients. Read more: https://lnkd.in/g_DQ-XqQ
-
ImmunityBio, Inc. reposted this
What comes next for bladder cancer patients after BCG? This latest episode of BCAN’s Bladder Cancer Matters podcast explores a critical question facing patients, clinicians, and researchers alike. In a conversation with ImmunityBio, Inc.'s Dr. Bobby Reddy, the discussion highlights how next-generation immunotherapies and innovative treatment approaches are reshaping care, especially for those with limited options. From addressing ongoing BCG shortages to advancing therapies that activate the body’s immune system, the future of bladder cancer treatment is evolving in meaningful ways. For healthcare professionals and advocates, staying informed on these developments is essential to improving patient outcomes and expanding access to care. If you’re working in this space, consider sharing this resource with your network. Increasing awareness helps drive better conversations, earlier decisions, and ultimately better care.
-
As we look ahead to the 2026 Bladder Cancer Advocacy Network walks, we're proud to stand alongside the bladder cancer community. Immunitybio is honored to sponsor these events and be part of the collective effort to raise awareness and support patients and caregivers in their cancer journeys. Register for a walk near you: https://lnkd.in/gapTqDgV
-
-
We're sharing our latest update, highlighting year-over-year revenue growth and financial metrics that support continued progress in our broader efforts. Access the full announcement: https://lnkd.in/gXgRcHEE
-
This World Health Day, we're reminded that progress in healthcare requires continued innovation. Our work centers on developing immune-based approaches designed to address areas of ongoing unmet need in cancer care. View our pipeline: https://lnkd.in/dYwrAigj
-
Glioblastoma is not only among the most common malignant brain tumors - it is also one of the most aggressive and difficult to treat. Advancing care requires new approaches. Learn more about how we are exploring the potential of the immune system to enhance how the body identifies and responds to cancers such as glioblastoma: https://lnkd.in/gm8a_Bfh
-
-
At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform. This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. Read more: https://lnkd.in/g5VGTdGH